Who are Active Comparator: FOLFOX plus cetuximab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/active-comparator-folfox-plus-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Active Comparator: FOLFOX plus cetuximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Active Comparator: FOLFOX plus cetuximab (Active Comparator: FOLFOX plus cetuximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen plus monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy regimen plus monoclonal antibody EGFR (cetuximab component); DNA (FOLFOX component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Active Comparator: FOLFOX plus cetuximab (Active Comparator: FOLFOX plus cetuximab) — Chinese Academy of Medical Sciences. FOLFOX plus cetuximab combines chemotherapy with an EGFR-targeting monoclonal antibody to kill colorectal cancer cells through dual mechanisms of DNA damage and growth factor receptor inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active Comparator: FOLFOX plus cetuximab TARGET	Active Comparator: FOLFOX plus cetuximab	Chinese Academy of Medical Sciences	phase 3	Chemotherapy regimen plus monoclonal antibody	EGFR (cetuximab component); DNA (FOLFOX component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen plus monoclonal antibody class)

Chinese Academy of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Active Comparator: FOLFOX plus cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/active-comparator-folfox-plus-cetuximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab